Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Date:5/6/2008

conduct additional trials or modify

its ongoing trials of this product candidate. Cadence currently expects

to receive guidance from the FDA in the second quarter of 2008.

o During the first quarter of 2008, Cadence also implemented several

design enhancements to Study 304, a Phase III clinical trial of

Acetavance for the treatment of acute pain in adults following abdominal

laparoscopic surgery. The trial design modifications included tightening

patient eligibility criteria, performing more frequent pain assessments

and increasing control of opioid medications. Cadence currently expects

to complete enrollment of this clinical trial in the third quarter of

2008 and announce top-line data in the second half of 2008.

o Also during the first quarter of 2008, Cadence initiated a multi-day

safety study of Acetavance in adult patients and a multi-day safety

study of Acetavance in pediatric patients.

o Assuming the successful outcome of Cadence's planned clinical trials for

Acetavance, and FDA concurrence with its proposed clinical development

plan, the company currently expects to submit a 505(b)(2) New Drug

Application (NDA) for this product candidate to the FDA in the first

half of 2009.

Enrollment

Acetavance Clinical Trials Study Phase Status

Treatment of pain following total

knee & hip replacement Sinatra(1) III Completed

Treatment of pain following abdominal

gynecologic surgery 301 III Completed

Treatment of fever in adults (vs. placebo) 302 III Completed

Treatment of fever in adults (onset

of action) 303 III Completed

Adult pharmacokinetics 101
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
9. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... FAIRFIELD, N.J. , Oct. 22, 2014 /PRNewswire/ ... a major transformation in the pain market, according ... Pain Insights, Inc., a firm providing market research ... management. Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... a scheduling change for hydrocodone combination products from ...
(Date:10/22/2014)... Vernak, RPh, of Vernak Farms Pharmacy in ... George Roentsch Scholarship by the Professional Compounding Centers of ... Houston during PCCA,s International Seminar, held October ... independent pharmacist and PCCA member who embodies the innovative ... well-known pharmacist in the compounding community. ...
(Date:10/22/2014)... Oct. 22, 2014 AVACEN Medical announced today ... 510 (k) OTC clearance by the U.S. Food and ... be marketed over the Internet for: the temporary ... and minor strains and sprains . Logo ... 100 (MSRP $2495) is a sophisticated medical device incorporating ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... Calif., May 27 Epeius Biotechnologies,( http://www.epeiusbiotech.com ) ... Feasibility Study of sequential targeted gene delivery -- ... will be presented at the,ASCO meetings in Chicago ... 2008).,Rexin-G and Reximmune-C are pathotropic (disease-seeking) nanoparticles,bearing a ...
... in high risk node-negative, population to show ... BRIDGEWATER, N.J., May 27 Sanofi-aventis ... de Mama) announced today,that for women with ... (post surgery) with Taxotere(R) (docetaxel) Injection,Concentrate as ...
Cached Medicine Technology:TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008) 2TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008) 3Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 2Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 3Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 4Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 5
(Date:10/22/2014)... News) -- The United States is now mandating ... of West Africa land at one of five ... the virus. In a statement released Tuesday, ... percent of air passengers from Guinea, Liberia and ... five airports -- New York City,s Kennedy International ...
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 With the Affordable ... national survey by the American Institutes for Research (AIR) finds ... how to use health insurance, but 42 percent say they ... plan’s details before signing up for coverage. , The AIR ... only 20 percent able to calculate correctly how much they ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
(Date:10/22/2014)... 2014 Losing Weight Your Body’s Way , ... you in the face, it certainly can be difficult to ... body an extra favor by doing it the healthy way? ... Instead, listen to your body, exercise regularly, and choose foods ... to losing weight; you need to exercise more and eat ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2
... sign of additional illness, suggest experts, , MONDAY, June 29 ... episode of low blood sugar during a hospital stay was ... the hospital and up to a year later, new research ... with diabetes who were hospitalized for a variety of ailments, ...
... GAI-122, an investigational injectable nanoemulsion formulated with, ... significant, neuro-protection in multiple in vitro ... that this injectable nanoemulsion formulation has the potential to, ... MARKHAM, ON, June 29 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ...
... (NYSE: CSC ) announced today that Modern ... Wah, chief medical officer and vice president of CSC,s ... their annual ranking of the 50 Most Powerful Physician ... 4,300 physician executives for the fifth annual ranking. Of ...
... Action , , KIRKLAND, Wash., June 29 If ... may not include a public option for long-term care, the ... illnesses or disabilities. If you,re in the market for long-term ... Gott says no; there,s too much to lose and little ...
... The American Society of Anesthesiologists (ASA) continues to ignore ... of its newly launched ,Anesthesia & Me, site. , ... having anesthesia without brain monitors. Awareness under anesthesia affects 0.1% ... main ASA site distracts attention from the much larger public ...
... Florida,s First ... Palm Beach County Florida has become the first in the State to receive formal recognition as ... ... Now Urgent Care Medical Centers of Palm Beach County Florida has become the first in the ...
Cached Medicine News:Health News:Low Blood Sugar in Hospital Tied to Higher Death Risk for Diabetics 2Health News:Low Blood Sugar in Hospital Tied to Higher Death Risk for Diabetics 3Health News:AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium 2Health News:CSC's Dr. Robert M. Wah Advances to Number Nine on 50 Most Powerful Physician Executives List 2Health News:Get Long-Term Care Protection Now; Don't Wait for Health Reform, Industry Leader Advises 2Health News:Get Long-Term Care Protection Now; Don't Wait for Health Reform, Industry Leader Advises 3Health News:American Society of Anesthesiologists Continues to Ignore Over Medication Risks 2Health News:MD Now Urgent Care Centers: First in Florida to Receive UCAOA Certification in Urgent Care 2Health News:MD Now Urgent Care Centers: First in Florida to Receive UCAOA Certification in Urgent Care 3
Latex agglutination slide test for the qualitative or quantitative determination of Cryptococcus neoformans antigen in CSF and serum....
... testing feature single-well ANA screen and ENA ... tests including dsDNA, and 6 individual ENA ... Scl-70 and Jo-1. In addition, our autoimmune ... products for Cardiolipins (IgA, IgG, IgM), Thyroglobulin, ...
... septicemia occur yearly in the U.S., with ... the organism and the determination of its ... Wampole ISOSTAT/ ISOLATOR Microbial System is a ... This technology is used to concentrate microorganisms ...
Hemagglutination slide test for the qualitative detection and quantitative determination of antibodies to streptococcal extracellular antigens in serum, plasma, or whole blood....
Medicine Products: